DLA PIPER LLP (US) for GALDERMA LABORATORIES, L.P.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement. Trade policies and agreements, including IP protections, and administrative tariff actions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KARINA LYNCH New | — |
| RACHEL PORTMAN New | Deputy Health Policy Director, Committee on Senate Health, Education, Labor and Pensions; Health Policy Assistant, Sen. Richard Burr; Intern, Sen. Robert Portman |
Pharmacy PHA
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement. Trade policies and agreements, including IP protections, and administrative tariff actions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KARINA LYNCH New | — |
| RACHEL PORTMAN New | Deputy Health Policy Director, Committee on Senate Health, Education, Labor and Pensions; Health Policy Assistant, Sen. Richard Burr; Intern, Sen. Robert Portman |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| GALDERMA GROUP AG | Switzerland | Switzerland | 100.0% | — |
| L'OREAL GROUPE | France | France | 20.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.